25BIO AG Research
Investment Thesis
25BIO is a small seed-stage biotech and healthtech investor based in Germany and Switzerland. Its site says the mission is to fund visionary entrepreneurs working on frontier technologies capable of transforming human health. The core argument is that not all biotechnology is equal: the industry has an innovation deficit, with a stark imbalance between capital invested and breakthroughs in understanding the human body. The firm says current approaches focus on incremental improvements to disease management, managing symptoms or the speed of decline, and it wants technologies that reach across scientific and engineering disciplines to prevent, reverse or alter the course of disease. It believes such transformational technologies create durable returns.
Third-party profiles (Whiteford Research Biobase) describe the firm as focused on longevity, healthy aging and age-related disease, including therapeutics and TechBio platforms for regeneration and aging, precision biomarkers for at-home monitoring and personalized prevention, and biowearables. These details come from the secondary source, not from the firm's own homepage, which stays at the level of transformative health technology.
Investment Criteria
The site names three pillars. Scale: biotech and healthtech solutions that scale, without insurmountable barriers to widespread distribution and adoption. Durability: the firm asks whether a company can be the dominant force when looking at what is three to four years behind it rather than only what is ahead. Timing: technology-market fit, meaning whether infrastructure, social habits and technology are colliding at the right moment, or whether the company is fifty years early.
Stage Focus
Seed stage biotech and healthtech investments globally. The team page says it writes its first cheque with substantial reserve for a follow-on, and that it understands the leap from lab-scale science to clinical validation is the first time the world hears about a company. Biobase adds that the firm invests from seed onward, after some technical risk has been removed.
Check Size
Not disclosed. No fund size, LP base or check range appears on the website or in public sources reviewed. The Swiss commercial register shows 25BIO AG was entered on 3 September 2025 with share capital of CHF 100,000, which suggests a very new vehicle. No fund size should be inferred from that.
Lead Tendency
Unknown. The firm reserves substantially for follow-ons and calls itself a hands-on partner ("we wear steel-toed boots"), but no lead or follow role is documented in any deal.
Recent Activity
No named investments, exits, fund announcements or press releases were found. The firm's own site has no portfolio page. 25BIO was listed among investor participants in the RESI JPM 2026 investor panels announced by Life Science Nation in December 2025, and appeared on the BioFuture 2025 registered-companies list, which shows it is active in the biotech investor ecosystem. The firm appears to have been founded in 2025 and is probably early in deployment, but fund status is unverified.
Portfolio Highlights
None publicly disclosed. Do not treat the portfolio as empty in fact; it is simply not published. Verify holdings directly with the firm before relying on any list.
Team
Swati Mehta is Managing Partner, described as a biotech incubator, builder and operator. She is the sole registered management person and signatory of 25BIO AG at the commercial register. Werner Seiz is Scientific Partner, described as a practitioner in AI in biomedical innovation and clinical development. The site calls the team investors who have built before. Both are based in Germany and Switzerland.
Decision Process
A two-person partnership with one managing partner and one scientific partner. Exact process is not documented, so this is listed as partnership with low confidence.
Founder Preferences
Visionary entrepreneurs with strong science and strong teams, working on frontier technologies where some technical risk has already been removed. The firm values founders who can show non-obvious opportunity, distribution potential and good timing.
Geographic Focus
Based in Germany and Switzerland and investing globally, with no stated regional restriction.
Gaps
Portfolio, fund size, check size, LPs and recent deals are not public. The main website returns errors for some automated fetchers; content was read through the F4-OS page reader. Treat this profile as a thin first pass.